Insilico's Fibrosis Drug Doubles as an Aging-Clock Ad
A Drug For The Lungs
Insilico Medicine designed rentosertib entirely with generative AI, its Pharma.AI platform proposing a molecule that blocks TNIK, an enzyme that sits inside a signaling pathway telling lung fibroblasts to keep laying down scar tissue after an injury should have finished healing. In idiopathic pulmonary fibrosis, that pathway never gets the stop signal, and lung tissue keeps stiffening until breathing fails. Nature Medicine published the Phase IIa GENESIS-IPF results in March 2025: 71 patients, 12 weeks, and at the 60mg daily dose forced vital capacity (roughly how much air a patient can forcibly exhale) improved by 98.4 mL while the placebo arm's lung function kept falling, down 20.3 mL. That gap between the two arms is why Insilico opened a Phase III trial in July 2026: 320 patients across 47 hospitals in China, led by Zuojun Xu at Peking Union Medical College Hospital with Nanshan Zhong and Chang Chen. Rentosertib is one of just fifteen AI-discovered drug programs to reach Phase III worldwide, out of more than 173 in clinical development. The trial's only endpoint that counts toward approval is annual FVC decline. Not biological age. Lung function, over a year, nothing else. That is the entire regulatory channel this drug has.
Reading Old Serum Again
On September 7, Insilico published a second paper, in Nature Biotechnology, built on serum already sitting in a freezer from that 71-patient trial. Researchers ran six aging clocks, statistical models trained to estimate biological age from molecular markers in blood, against those leftover samples and found the readings dropped in patients on rentosertib. Nobody enrolled those 71 IPF patients to test an aging hypothesis; the samples just happened to still be there when someone asked a new question of them. Insilico's own scientists included the caveat plainly, that the finding 'does not establish rentosertib as an anti-aging therapy.' Insilico doesn't only sell drugs. It sells the aging clocks. The company markets a 'Virtual Aging Cell' biological-age analytics platform to other biotech and consumer-longevity firms, a data business running parallel to and separate from the drug pipeline, and a peer-reviewed validation of six aging clocks is exactly the credential that business needs. Insilico listed on the Hong Kong exchange on December 30, 2025, raising HK$2.277 billion, shares up 24.7% on debut. Two businesses, one press release. They are not the same claim.
Headlines Ahead Of Data
That same day, Bloomberg and the New York Times both ran the aging-clock finding under headlines built around a drug 'reversing aging.' Phase III enrolled its first patients in July 2026 and reads out around 2027, on FVC alone. No regulator anywhere, not the FDA, not China's NMPA, accepts an aging clock as a trial endpoint, and geroscience researchers themselves keep making the same point Insilico's own paper concedes: the first question is whether the underlying biology changed, not whether a clock moved. This desk has argued before that most consumer biomarker products fail replication and the ones that survive are the boring measures, VO2max, grip strength, sleep regularity. The aging clock here fails that same replication test and is sold as commercial analytics anyway, and this week a Nature Biotechnology stamp is doing work for it regardless of what happens to the drug. The people this actually turns on are the 320 IPF patients enrolling across those 47 Chinese hospitals, whose lung function over the next year is the only data that decides whether rentosertib works. None of them will be tested on an aging clock as part of that decision.
Phase III reads out on lung function alone, around 2027, and will not care what six aging clocks said about a trial already published. The aging-clock paper is already circulating as validation for a business Insilico owns outright. The company itself says the two should not be conflated. Bloomberg and the New York Times ran with 'reversing aging' anyway.
Sources
- Bloomberg -- AI-discovered drug reverses aging markers in study, biotech says (bloomberg.com)
- Nature Medicine -- Phase IIa GENESIS-IPF trial results (nature.com)
- Insilico Medicine -- Phase III trial announcement (insilico.com)
- South China Morning Post -- Insilico HKEX listing and debut (scmp.com)
- BiopharmaAPAC -- Asia Pacific's geroscience paradox (biopharmaapac.com)
- New York Times -- AI Drug May Slow Aging (nytimes.com)